Mesalazine controlled release - Shire

Drug Profile

Mesalazine controlled release - Shire

Alternative Names: Lialda; MD-0901; Mesalamine oral - Shire Pharmaceutical Group; Mesalazine MMX™; Mesavance; Mezavant; Mezavant XL; MMX Mesalamine; SPD 476

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Mochida Pharmaceutical; Shire
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis
  • Discontinued Diverticulitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Apr 2015 The product is approved for Ulcerative colitis and is in phase-III development in South Korea and Japan, respectively
  • 22 Oct 2014 Phase-III clinical trials in Ulcerative colitis (In adolescents, In children) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top